Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

2.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

3.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.

4.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

5.

Maraviroc for previously treated patients with R5 HIV-1 infection.

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.

6.

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN.

J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523.

PMID:
18476293
7.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.

PMID:
18476292
8.

Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.

TMC125-C223 Writing Group, Nadler JP, Berger DS, Blick G, Cimoch PJ, Cohen CJ, Greenberg RN, Hicks CB, Hoetelmans RM, Iveson KJ, Jayaweera DS, Mills AM, Peeters MP, Ruane PJ, Shalit P, Schrader SR, Smith SM, Steinhart CR, Thompson M, Vingerhoets JH, Voorspoels E, Ward D, Woodfall B.

AIDS. 2007 Mar 30;21(6):F1-10.

PMID:
17413684
9.

Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India.

Pujari SN, Dravid A, Naik E, Bhagat S, Tash K, Nadler JP, Sinnott JT.

J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):199-202.

PMID:
15905737
10.

New HIV Drugs in Development, 2005.

Nadler JP, Phillips MC.

Curr Infect Dis Rep. 2005 May;7(3):221-226.

PMID:
15847725
11.

Anemia prevalence and associated risk factors in a single-center ambulatory HIV clinical cohort.

Wills TS, Nadler JP, Somboonwit C, Vincent A, Leitz G, Marino K, Naik E, Powers S, Khan N, Laartz B.

AIDS Read. 2004 Jun;14(6):305-10, 313-5.

PMID:
15243966
12.

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.

Rodriguez-French A, Boghossian J, Gray GE, Nadler JP, Quinones AR, Sepulveda GE, Millard JM, Wannamaker PG.

J Acquir Immune Defic Syndr. 2004 Jan 1;35(1):22-32.

PMID:
14707788
13.

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.

Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Lancaster CT, Hernandez JE, Pappa KA; ESS40011 (STARR) Study Team.

BMC Infect Dis. 2003 Jun 10;3:10.

14.

Open-label study of a twice-daily indinavir 800-mg/ritonavir 200-mg regimen in HIV-infected adults failing a protease inhibitor regimen.

Katner HP, Paar DP, Nadler JP, Jensen EH, Wilson HM, Finn TS, Petruschke RA, Zeldin RK.

J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):483-7.

PMID:
12473836
15.

Predicting death from HIV/AIDS: a case-control study from Florida public HIV/AIDS clinics.

Lieb S, Brooks RG, Hopkins RS, Thompson D, Crockett LK, Liberti T, Jani AA, Nadler JP, Virkud VM, West KC, McLaughlin G.

J Acquir Immune Defic Syndr. 2002 Jul 1;30(3):351-8.

PMID:
12131573
16.

Daily dosing of highly active antiretroviral therapy.

Rosenbach KA, Allison R, Nadler JP.

Clin Infect Dis. 2002 Mar 1;34(5):686-92. Epub 2002 Jan 25.

PMID:
11823957
17.

Why didn't I go to Durban?

Nadler JP.

AIDS Read. 2000 Jul;10(7):441-2. No abstract available.

PMID:
10932848
18.

Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial.

Davey RT Jr, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, Nadler JP, Chaitt DG, Dewar RL, Sahner DK, Duliege AM, Capra WB, Leong WP, Giedlin MA, Lane HC, Kahn JO.

JAMA. 2000 Jul 12;284(2):183-9.

PMID:
10889591
19.

A randomized trial of interferon alpha therapy for HIV type 1 infection.

Haas DW, Lavelle J, Nadler JP, Greenberg SB, Frame P, Mustafa N, St Clair M, McKinnis R, Dix L, Elkins M, Rooney J.

AIDS Res Hum Retroviruses. 2000 Feb 10;16(3):183-90.

PMID:
10710206
20.

Rapidly progressive herpetic retinal necrosis: a blinding disease characteristic of advanced AIDS.

Ormerod LD, Larkin JA, Margo CA, Pavan PR, Menosky MM, Haight DO, Nadler JP, Yangco BG, Friedman SM, Schwartz R, Sinnott JT.

Clin Infect Dis. 1998 Jan;26(1):34-45; discussion 46-7.

PMID:
9455507

Supplemental Content

Loading ...
Support Center